Barclays
NVAX icon

Barclays’s Novavax NVAX Stock Holding History

Barclays’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$239K – 5173
2024
Q1 		$239K Sell
50,000
-450,000
-90% -$2.09M ﹤0.01% 4020
2023
Q4 		$2.4M Buy
+500,000
New +$3.06M ﹤0.01% 2771
2023
Q2 		– Sell
-800,000
Closed -$5.54M – 4928
2023
Q1 		$5.54M Buy
800,000
+625,000
+357% +$5.75M ﹤0.01% 1474
2022
Q4 		$1.8M Buy
+175,000
New +$3.09M ﹤0.01% 2331
2022
Q1 		– Sell
-165,800
Closed -$23.7M – 5427
2021
Q4 		$23.7M Buy
165,800
+143,500
+643% +$24.7M 0.01% 880
2021
Q3 		$4.62M Sell
22,300
-120,800
-84% -$26.6M ﹤0.01% 1690
2021
Q2 		$30.4M Buy
143,100
+123,100
+616% +$22.6M 0.01% 703
2021
Q1 		$3.63M Buy
20,000
+14,600
+270% +$2.91M ﹤0.01% 1786
2020
Q4 		$602K Sell
5,400
-9,800
-64% -$1.04M ﹤0.01% 3128
2020
Q3 		$1.65M Buy
+15,200
New +$1.85M ﹤0.01% 2271
2019
Q3 		– Sell
-11,250
Closed -$66K – 6997
2019
Q2 		$66K Hold
11,250
– – ﹤0.01% 5953
2019
Q1 		$124K Buy
+11,250
New +$355K ﹤0.01% 5196
2018
Q1 		– Sell
-2,500
Closed -$62K – 7247
2017
Q4 		$62K Buy
+2,500
New +$61K ﹤0.01% 5616
2016
Q4 		– Sell
-24,660
Closed -$1.03M – 6761
2016
Q3 		$1.03M Buy
+24,660
New +$3.18M ﹤0.01% 2598

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's NVAX Position: Q1 2026 in Review

Barclays increased its Novavax (NVAX) stake by 8.1% in Q1 2026, buying an estimated $805K and bringing the position to 1,191,079 shares worth $9.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

Barclays first reported a position in NVAX in Q2 2013 and has held it in 52 quarters since. The position peaked at $44.3M in Q2 2021. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Barclays held 1,191,079 shares of Novavax worth $9.7M as of Q1 2026.
  • Barclays bought 88,779 Novavax shares in Q1 2026, an estimated $805K.
  • Novavax made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1465 holding.
  • Barclays first reported a position in Novavax in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Novavax position peaked at $44.3M in Q2 2021.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.